Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Read more about Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance.
Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC). Read more about Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).
Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer. Read more about Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer.
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Read more about MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.
Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Read more about Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).
Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series. Read more about Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series.
Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. Read more about Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer.
Practice patterns of primary EBRT with and without ADT in prostate cancer treatment. Read more about Practice patterns of primary EBRT with and without ADT in prostate cancer treatment.
BRCAness and prostate cancer: diagnostic and therapeutic considerations. Read more about BRCAness and prostate cancer: diagnostic and therapeutic considerations.
